TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

projections, expectations, predictions, or forward-looking statements, whether because of new information, future events, or developments, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 5th, 2026. And with that, I will now turn the call over to Waleed Hasmeen, President and Chief Executive Officer. Thank you so much, Hannah. Good afternoon, everyone, and welcome to Transmedics First Quarter's 2026 Earnings Call. As always, joining me today is Gerardo Hernandez, our Chief Financial Officer. Our vision has always been bold and growth-oriented. Since inception, Transmedics has been relentless in our pursuit to transform organ transplant therapy by increasing utilization of donor organs and improving the clinical outcomes of transplant patients through technology and service innovation and by disrupting the status quo. To accomplish this, we've been deliberate yet aggressive in our strategic investment in growth initiatives. We believe that 2026 is a critical and transformational year that stands to cement transmedics near, mid, and long-term growth trajectories and global market position. In the U.S., we're actively engaged in growing our heart and lung franchises by advancing our enhanced heart and de novo lung programs to expand our clinical evidence to support broader adoption. In parallel, We are also completing the development of the OCS kidney platform using our Gen 3.0 platform. Our OCS kidney platform will enable us to access the largest segment of the global transplant market, which is kidney transplantation. This will happen for the first time in the history of transmedics. We strongly believe that once regulatory approvals are in hand, OCS kidney will derive significant growth fo...